Skip to main content
main-content

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

Editors' pick

12-05-2018 | Diabetes distress | Editorial | Article

Diabetes distress: What’s in a name?

Sanjay Kalra and Psychiatrist Yatan Pal Singh Balhara question whether “diabetes distress” is well understood outside of the diabetes field and consider whether alternative terminology may help to bridge the knowledge gap.

11-28-2018 | SGLT2 inhibitors | Commentary | Article

What can real-world studies really tell us about amputation risk for SGLT2 inhibitors?

John Wilding considers the real-world studies examining the association between SGLT2 inhibitors and amputation risk in patients with type 2 diabetes.

12-03-2018 | Liraglutide (T2DM) | medwireNews | News

Older type 2 diabetes patients may derive greatest liraglutide benefits

The LEADER investigators report that treatment with the glucagon-like peptide-1 receptor agonist liraglutide may be of particular benefit in the oldest patients with type 2 diabetes.

Latest from across the site

12-07-2018 | DPP-4 inhibitors | News

Possible bile duct cancer risk with incretin-based medications

Data from clinical practice suggest the possibility of an increased relative risk for cholangiocarcinoma among patients taking incretin-based antidiabetes medications, although the absolute risk remains small.

Source:

BMJ 2018; 363: k4880
BMJ 2018; 363: k5155

12-07-2018 | Liraglutide (T2DM) | News

Liraglutide cardioprotection replicated in real-world data

Registry data from Denmark and Sweden uphold the cardioprotective effects of liraglutide observed in randomized trials, with the strongest effects seen in patients with established cardiovascular disease.

Source:

Lancet Diabetes Endocrinol 2018; doi:10.1016/S2213-8587(18)30320-6
Lancet Diabetes Endocrinol 2018; doi:10.1016/S2213-8587(18)30340-1

12-07-2018 | Pregnancy | News

Metformin plus lifestyle advice does not improve pregnancy outcomes for obese women

Giving pregnant obese women metformin in addition to dietary and lifestyle advice does not reduce the likelihood of them having a baby with a high birthweight, show the results of the GRoW randomized trial.

Source:

Lancet Diabetes Endocrinol 2018; doi:10.1016/S2213-8587(18)30337-1
Lancet Diabetes Endocrinol 2018; doi:10.1016/S2213-8587(18)30310-3

12-05-2018 | Empagliflozin | News

Empagliflozin beneficial for uncontrolled nocturnal hypertension

The addition of empagliflozin reduces nighttime blood pressure in older diabetes patients who have nocturnal hypertension despite medication including angiotensin receptor blockers, show findings from a randomized trial.

Source:

Circulation 2018; doi:10.1161/CIRCULATIONAHA.118.037076

12-05-2018 | Diabetes distress | Editorial | Article

Diabetes distress: What’s in a name?

Sanjay Kalra and Psychiatrist Yatan Pal Singh Balhara question whether “diabetes distress” is well understood outside of the diabetes field and consider whether alternative terminology may help to bridge the knowledge gap.

Authors:
Sanjay Kalra, Yatan Pal Singh Balhara

12-05-2018 | Non-alcoholic fatty liver disease | Article

A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue?

Lonardo A, Lugari S, Ballestri S et al. Acta Diabetol 2018. doi: 10.1007/s00592-018-1266-0

medwireNews@EASD2018

The 2018 EASD Annual Meeting took place in Berlin from the 1st to 5th October. Click here for news and expert commentary, including the EASE, PREVIEW, and HARMONY trials.

Meet our Editorial Board

New Content Item Meet our Advisory Board

Latest from us on Twitter

Trending this week

image credits